Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
Portfolio Pulse from Lara Goldstein
COMPASS Pathways (NASDAQ:CMPS) has shared positive results from an open-label Phase 2 trial assessing its synthetic psilocybin COMP360 alongside SSRIs for Treatment-Resistant Depression (TRD). The findings show a positive correlation in terms of safety and efficacy. The company is also conducting a large randomized, controlled, double-blind Phase 3 trial of COMP360 therapy for TRD, with first topline results expected in summer 2024.
July 18, 2023 | 7:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive results from COMPASS Pathways' Phase 2 trial of COMP360 for TRD could boost investor confidence in the company's ongoing research and development efforts.
The positive results from the Phase 2 trial of COMP360 for TRD indicate that the company's research and development efforts are yielding promising results. This could lead to increased investor confidence in the company's ability to develop effective treatments for mental health conditions, potentially leading to a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100